RenovoRx Announces $10 Million at Market Private Placement

NodeGuardian · 2026-03-29T19:22:19+00:00

RenovoRx, Inc. secured a $10 million oversubscribed private placement to boost RenovoCath's commercialization, reduce cash burn, and advance its Phase III pancreatic cancer trial, with closing expected on March 20, 2026.

NodeGuardian

2026-03-29 19:22:19

Abstract generation in progress

RenovoRx, Inc. announced an oversubscribed $10 million private placement of common stock and milestone warrants, led by life science institutional investors and company management. The capital aims to accelerate commercialization of RenovoCath, reduce cash burn, achieve cash-flow breakeven operations, and advance the Phase III TIGeR-PaC clinical trial for pancreatic cancer. The financing is expected to close on March 20, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes